Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABH001 for stalled chronic cutaneous wounds in generalized epidermolysis bullosa
2012-001815-21Phase 3Terminated
- Sponsor
- Takeda
- Start
- Sep 2012
- Modality
- Cell Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Dermagraft in epidermolysis bullosa (EB) (2 arms), sponsored by Takeda. Primary endpoint: Reduction in wound surface area. Started Sep 2012; status: terminated.
02
Drugs
Dermagraft
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on 2012-001815-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001815-21.